Current multidisciplinary management of brain metastasesMichael J. Moravan, John P. Kirkpatrick, John H. Sampson et al.|Cancer|2020Cited by 130
Safety of administration of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, before curative-intent treatment in patients with HPV16+ oropharyngeal squamous cell carcinoma.Sidharth V. Puram, Douglas R. Adkins, Jessica Ley et al.|Journal of Clinical Oncology|2025Cited by 4
Patient‐Reported Swallowing Outcomes in HPV+ Oropharyngeal Cancer by Postoperative Chemoradiation Dose in MINT and E3311Theresa Tharakan, Ryan S. Jackson, Sidharth V. Puram et al.|Otolaryngology|2025Cited by 2
Establishing an integrated approach to head and neck cancer treatment and prevention: The Robert Ebert and Greg Stubblefield Head and Neck Tumor Center ModelRyan S. Jackson, Sandra Dimitri, Karolina A. Plonowska‐Hirschfeld et al.|Oral Oncology|2025Cited by 1
Characterization of dynamic changes in tumor-infiltrating lymphocytes (TIL) after neoadjuvant administration of CUE-101, an HPV16 E7-HLA-IL2 fusion protein, to patients with HPV+ locally advanced oropharyngeal squamous cell carcinoma (LA-OPSCC).Jesse M. Zaretsky, Sidharth V. Puram, Riley Mullins et al.|Journal of Clinical Oncology|2025Cited by 0